Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir
In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks post-treatment
Atea's new hepatitis C medicine worked about as well as an older medicine in a big test—both cured the virus in roughly 94% of patients. When a new medicine works as well as an existing one, it shows the company has a real option to offer doctors, though it doesn't mean one is clearly better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.